NCT03277352 · OUTCOME

Phase 2: Complete Response Rate (CRR) Based on RECIST v1.1

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies · Source last updated 2021-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months

What was measured

Defined as the percentage of checkpoint inhibitor-naive melanoma participants who have a CR based on investigator assessment per RECIST v1.1

Analysis population: The study was terminated early and no participants enrolled in Phase 2 of the study.

INCAGN01876 in combination with pembrolizumab and epacadostat

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
INCAGN01876 + Pembrolizumab + Epacadostat	0

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

description

Defined as the percentage of checkpoint inhibitor-naive melanoma participants who have a CR based on investigator assessment per RECIST v1.1

groups

population Description

The study was terminated early and no participants enrolled in Phase 2 of the study.

reporting Status

POSTED

time Frame

Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months

title

Phase 2: Complete Response Rate (CRR) Based on RECIST v1.1

type

PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice